Rejuran Becomes a Must-Have for Medical Tourists... Expanding Global Presence
Cosmetics Division Achieves High Growth... Broader Distribution Channels Including Sephora

According to securities industry analysis, PharmaResearch has secured mid- to long-term growth drivers by diversifying its portfolio beyond a domestic sales structure, focusing on exports and cosmetics.


On June 25, according to Samsung Securities, researcher Jeong Donghee stated the previous day, "PharmaResearch continues to present an attractive valuation (stock price relative to corporate value), even after adjusting expectations due to a lack of supply-demand balance and short-term momentum." The investment opinion of 'BUY' was maintained. However, due to a lack of short-term share price catalysts, the target price was lowered from 5 million won to 4 million won. The closing share price the previous day was 304,500 won.


"PharmaResearch, Biggest Beneficiary of Korea's Medical Tourism... Target Price Lowered" [Click e-Stock] View original image

PharmaResearch's flagship product, Rejuran, was launched in Korea 10 years ago and has become an essential item for dermatology clinics. Notably, it is among the few Korean products favored by foreign tourists visiting Korea for medical services, making the company one of the biggest beneficiaries of Korea's medical tourism industry.


Researcher Jeong projected, "With the launch of energy-based devices (EBD) scheduled for the second half of this year and the launch of highly concentrated Rejuran, which is expected either next year or in 2028, the company will be able to stimulate domestic demand and secure mid- to long-term export growth drivers."


Exports are also on an upward trend. Exports to Ukraine reached USD 9.5 million last year, up 167.3% year-on-year, and exports to Australia soared to USD 4.3 million, up 348.0% from the previous year. The United Arab Emirates (UAE) recorded shipments of USD 370,000 in the first quarter, representing 62.8% growth compared to the previous quarter. In Western Europe, exports amounted to USD 2.2 million in April, which exceeded the minimum order quantity (MOQ), and additional shipments are expected within this month.


The cosmetics division is also showing high growth. In the United States, after focusing on Amazon-based distribution, the company will make a full-scale entry into the offline market this year by securing placement in Sephora. Cosmetics exports to the United States increased from USD 400,000 in 2024 to USD 9.3 million last year. As of last month, exports had already reached USD 7.6 million this year, indicating rapid growth.


Researcher Jeong analyzed, "With increased shipments in preparation for Amazon Prime Day this month, the second quarter cosmetics sales are expected to reach 30.5 billion won, up 56.5% year-on-year and 13.5% quarter-on-quarter," adding, "The proportion of cosmetics sales is projected to reach 29% this year, up 4 percentage points from the previous year."


The main investment points for this year include: ▲structural growth from Western Europe shipments, ▲export volume growth due to an increased number of approved countries, ▲a rebound in domestic demand driven by benefits from medical tourism, and ▲the impact of expanding distribution channels for cosmetics.



However, researcher Jeong explained, "While annual estimate revisions are minimal, there has been a short-term gap in momentum around the first quarter earnings announcement," adding, "Reflecting the continued shift in supply-demand toward large-cap stocks, we have lowered the target price."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing